[Skip to Content]
[Skip to Content Landing]
Comment & Response
July 2015

No Evidence of Disease Activity in Multiple Sclerosis

Author Affiliations
  • 1Multiple Sclerosis Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts
  • 2A. A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown
  • 3Multiple Sclerosis Center, University of California, San Diego
 

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Neurol. 2015;72(7):835-836. doi:10.1001/jamaneurol.2015.0587

To the Editor No evidence of disease activity (NEDA) is becoming an important secondary outcome measure in multiple sclerosis (MS) clinical trials. In this context, the article by Rotstein and colleagues,1 demonstrating that NEDA at 2 years has potential prognostic significance, is timely. Interestingly, the authors1 found a dissociation between clinical and magnetic resonance imaging (MRI) disease activity, raising the question of whether the lack of disease progression truly reflects evidence of absence or absence of evidence.

×